InvestorsHub Logo
Followers 17
Posts 936
Boards Moderated 0
Alias Born 04/26/2010

Re: loanranger post# 239183

Sunday, 09/02/2018 5:02:09 PM

Sunday, September 02, 2018 5:02:09 PM

Post# of 403047
I did dig into the article you are quoting some time ago. I believe the author uses Polymedix paresthesias study results without proper attribution to comment on IPIX (CTIX then) phase 2b trial. So you are not confused, Da author is confusing.

A tidbit that is likely to be outdated and possibly mostly wrong if not this year then next: 'ION channels' listed by the author and in Polymedix study are (well, were when I last time checked) associated with pain sensing. If that's still the case then maybe dulling pain is not so bad for antibiotic side effect.

Happy that we agree on Rosen's quality as reference.

A Disclosure of potentially misleading omission: I was not quite right about the awareness some people might have had about the level of systemic exposure from topical application of Brilacidin at the time of IPIX p2b trial. There was a study about Brilacidin as ocular anti-infective started while Polymedix had Brilacidin and finished when B was already Cellceutix property. In the study author notes that B is effective when epithelium is abraded but not when it is intact. The first published indication I know of that talks about Brilacidin having very low absorption rate thru intact epithelium (Am I getting fancy here?). May well explain Leo & Co's decidedly changing direction towards cheaper studies with abraded stuff: OM and UP/C.

Link:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742993/

"I would rather have questions that can't be answered than answers that can't be questioned." Richard P. Feynman

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News